These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol. Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Certolizumab Pegol in the Treatment of Psoriasis in a Cohort of Patients With Psoriatic Arthritis. Reina D; Vidal D Actas Dermosifiliogr (Engl Ed); 2020 Oct; 111(8):704-705. PubMed ID: 32593595 [No Abstract] [Full Text] [Related]
4. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928 [No Abstract] [Full Text] [Related]
5. Successful Use of Certolizumab Pegol for Refractory Psoriatic Arthritis Triggered by COVID-19 Infection. Ohmura SI; Homma Y; Hanai S; Miyamoto T Intern Med; 2022 Feb; 61(3):433-438. PubMed ID: 34803106 [TBL] [Abstract][Full Text] [Related]
6. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. Deeks ED BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400 [TBL] [Abstract][Full Text] [Related]
8. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. Oelke KR; Chambenoit O; Majjhoo AQ; Gray S; Higgins K; Hur P J Comp Eff Res; 2019 Jun; 8(8):607-621. PubMed ID: 30912454 [No Abstract] [Full Text] [Related]
9. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421 [TBL] [Abstract][Full Text] [Related]
10. A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation. Lauro W; Picone V; Abategiovanni L; Vastarella M; Gallo L; Fabbrocini G; Megna M Int J Dermatol; 2023 Feb; 62(2):e70-e72. PubMed ID: 35579302 [No Abstract] [Full Text] [Related]
11. Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies. Domańska B; Stumpp O; Poon S; Oray S; Mountian I; Pichon C Adv Ther; 2018 Jan; 35(1):100-115. PubMed ID: 29222625 [TBL] [Abstract][Full Text] [Related]
12. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis. Reygaerts T; Mitrovic S; Fautrel B; Gossec L Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303 [TBL] [Abstract][Full Text] [Related]
13. Nail Psoriasis Treated With Certolizumab Pegol in Patients With Psoriatic Arthritis: Preliminary Observation. Mazzeo M; Dattola A; Cannizzaro MV; Bianchi L Actas Dermosifiliogr (Engl Ed); 2019 Mar; 110(2):169-171. PubMed ID: 29866366 [No Abstract] [Full Text] [Related]
14. Polyethylene glycol: an underrecognized compound in certolizumab pegol and Movicol that may cause anaphylaxis. McCabe E; Tormey V; Doran JP Rheumatology (Oxford); 2020 Apr; 59(4):908-910. PubMed ID: 31598712 [No Abstract] [Full Text] [Related]
15. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes? Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis. Nishimura A; Minegishi Y; Kwamura K; Ichino A; Uchiyama K Rheumatol Int; 2015 Sep; 35(9):1601-2. PubMed ID: 25645901 [No Abstract] [Full Text] [Related]